SPP100 (Aliskiren) Regimen in Patients With Severe Hypertension

Novartis

Status and phase: Completed; Phase 3

Conditions: Hypertension

Treatments: Drug: Aliskiren

Study type: Interventional

Funder types: Industry

Identifiers

NCT00299806

CSPP100A1304

Details and patient eligibility

About

Assessing the safety and efficacy of SPP100 (Aliskiren) regimen in patients with severe hypertension

Enrollment: 39 patients

Sex: All

Ages: 20 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age: 20 - 80 years old
• Gender: Male or female
• Status: Outpatients
• severe hypertension

Exclusion criteria

• Patients with a clinically significant allergy
• Patients who have received other investigational drug
• Alcoholic patients

Other protocol-defined inclusion/exclusion criteria may apply

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)